Hello – When central banks, retail investors and industry all clamor for the same metal, prices don’t just rise—they can launch. Our 2026 Gold Forecast: A Perfect Storm for Demand explains why spot gold could break past $4,000 this year and provides guidance on how to position yourself before it happens. Inside, you’ll discover: -
Why net-buying by central banks just hit a record first-half total, led by Turkey and India. -
How rate cuts and a weakening dollar create a powerful tailwind for precious metals. -
Three practical ways to add gold—from physical bars to high-margin mining stocks paying dividends. -
Price targets suggest $4,000 per ounce if current trends persist. This concise PDF outlines the catalysts, risks, and tactics so you can decide whether to hold the metal, own the miners, or both. 👉 Download your free Gold Forecast now. No cost. No credit card. Just actionable research before the crowd sees the signal. To your investing edge, Matthew Paulson
Founder & CEO, MarketBeat P.S. Only about 2–5 % of investors own physical gold today. If the other 95% start buying, you’ll want to be in first. Grab the report now while it’s still free.
More Reading from MarketBeat Members of Congress Bought These 5 Stocks—Should You?By Chris Markoch. Posted: 3/18/2026. 
Key Points - Congressional disclosures highlighted five stocks recently traded by lawmakers, including BigBear.ai, Eli Lilly, and Broadcom.
- AI, defense, semiconductors, and GLP-1 healthcare trends appear across several trades, pointing to sectors with strong growth narratives.
- While disclosures lag by up to 45 days, tracking congressional trades can provide useful watchlist ideas for individual investors.
- Special Report: Elon's "Hidden" Company
Lawmakers from both parties have recently proposed banning members of Congress from trading individual stocks while in office. That impulse dates back to the STOCK Act of 2012, which was intended to be the fix. The law requires politicians to disclose trades publicly within 45 days of a transaction. Critics say the STOCK Act doesn't go far enough. More recent proposals — including the ETHICS Act and the TRUST in Congress Act — would prohibit active stock trading by members altogether. The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions. See the 5 stocks to avoid But Congress moves slowly. Until and unless those bills become law, the 45-day disclosure window is one of the few tools everyday investors have to see where elected officials are putting their own money. A scan of required filings over the past 90 days identified five stocks worth watching, from a small-cap AI defense play to a large-cap semiconductor giant at the center of the artificial intelligence infrastructure boom. BigBear.ai: A Small-Cap AI Defense Play Getting Repeat Attention Representative Lisa McClain of Michigan made two separate purchases of BigBear.ai (NYSE: BBAI) in February, first on the 4th and again on the 6th. Combined, those purchases were valued between $16,000 and $65,000. BigBear.ai is a small-cap decision-intelligence company that derives a significant portion of its revenue from U.S. government contracts in defense and national security. McClain is not a one-time buyer. In August 2024 she reportedly became the first member of Congress to disclose ownership of BBAI stock, and her repeat purchases suggest this is more than a single, incidental trade. Her seat on the Financial Services Subcommittee on National Security may provide relevant context for investors to consider. Cracker Barrel: A Quick Trade From a Top Congressional Performer Representative Tim Moore of North Carolina was named the top-performing member of Congress for stock trades in 2025, with a reported 52% gain. Moore was active in Cracker Barrel (NASDAQ: CBRL) around the turn of the year. He purchased CBRL on Dec. 31 and then sold a larger position on Jan. 5, locking in what appears to be a short-term profit on a beaten-down restaurant stock. The buy was in the $15,000–$50,000 range; the sale was $50,000–$100,000. That looks more tactical than a long-term conviction, but when the member who outperformed the S&P 500 by a wide margin makes a move, even a brief trade tends to draw attention. Simply Good Foods: A Double Buy on a Beaten-Down Nutrition Stock Simply Good Foods (NASDAQ: SMPL) is another interesting purchase by Congressman Moore. He made two buys in February, on the 3rd and again on the 11th, each valued between $15,000 and $50,000. According to Quiver Quantitative data, Moore appears to be the first member of Congress to buy SMPL stock in recent years. Simply Good Foods, the company behind Atkins and Quest nutrition products, has seen its stock fall roughly 53% over the past year. Moore's double purchase suggests he's buying into weakness with a new position. There's also a potential macro tailwind: as GLP-1 weight-loss drugs shift consumer behavior toward higher-protein, lower-carb options, certain consumer staples could benefit. Eli Lilly: GLP-1 Momentum and an Upcoming Obesity Drug Catalyst Representative David Taylor of Ohio purchased Eli Lilly (NYSE: LLY) on Feb. 26; the trade was disclosed on March 6. The timing coincided with public comments from Lilly's CFO confirming the company is on track to launch its oral obesity drug, orforglipron, in the second quarter of 2025, pending FDA approval. To be fair, orforglipron has been widely discussed for months, and the disclosure timing is standard under the STOCK Act. Still, the sequence of events is the sort that attracts attention. The fundamental case for LLY is clear: it holds roughly 60% of the U.S. GLP-1 market and reportedly has $1.5 billion in pre-launch inventory ready to ship within a week of approval. Additionally, Medicare coverage for an oral pill could begin as early as April, potentially at around $50 per month for eligible patients. Broadcom: Multiple Congressional Buys in a Leading AI Chip Stock Broadcom (NASDAQ: AVGO) stands out because the buying wasn't concentrated in a single member—three different members of Congress purchased AVGO shares in the past 90 days. Representative Gilbert Ray Cisneros Jr. bought shares in October, November and December. Senator Shelley Moore Capito purchased AVGO in early February. And David Taylor, the same Ohio congressman who bought Eli Lilly, picked up Broadcom on Jan. 29. Broadcom reported $12 billion in AI revenue for fiscal 2025, a 74% year-over-year increase, and guided for $10.7 billion in AI revenue in Q1 2026 alone. The company is also a significant federal contractor, which means members of Congress may have more than just Wall Street research shaping their views. Congressional Trades Are a Clue, Not a Trading Signal Investors should remember that congressional trade disclosures are one data point, not a buy or sell signal. By the time a disclosure is public, the trade is often already 45 days old and the thesis may be reflected in the stock price. Correlation between a member's role and a purchase does not imply wrongdoing. That said, seeing where informed, well-connected investors place their own money — and noting when multiple members converge on the same name — can be a reasonable part of an investor's research process. These five stocks may be worth adding to a watchlist, but do independent research before taking any action. | 
Post a Comment
Post a Comment